Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Policy
  3. Access to Cancer Medicines and Technologies

Accessibility and Availability of Medicines and Technologies

ESMO is working to improve the availability of anticancer medicines and technologies in Europe and worldwide

The availability of cancer medicines is crucial for medical oncologists to be able to treat patients according to the evidence-based ESMO Clinical Practice Guidelines.

ESMO has conducted several studies to understand the availability and accessibility of antineoplastic medicines, biomolecular technologies and opioids.

Discover them below

  • ESMO Studies on the Availability, Out-of-Pocket Costs and Accessibility of Antineoplastic Medicines. Read more
  • ESMO Study on Availability and Accessibility to Biomolecular Technologies in Oncology in Europe. Read more
  • Formulary Availability and Regulatory Barriers to Accessibility to Legitimate Medical Use of Opioids for Cancer Pain. Read more

You may also be interested in...

Related Links

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.